Vasculitis - Pipeline Review, H2 2014

Published: Dec, 2014 | Pages: 106 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)

Vasculitis - Pipeline Review, H2 2014

Summary

Global Markets Direct's, 'Vasculitis - Pipeline Review, H2 2014', provides an overview of the Vasculitis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Vasculitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Vasculitis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Vasculitis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Vasculitis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Vasculitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Vasculitis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Vasculitis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Vasculitis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Vasculitis Overview 8
Therapeutics Development 9
Pipeline Products for Vasculitis - Overview 9
Pipeline Products for Vasculitis - Comparative Analysis 10
Vasculitis - Therapeutics under Development by Companies 11
Vasculitis - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Vasculitis - Products under Development by Companies 16
Vasculitis - Companies Involved in Therapeutics Development 17
AnGes MG, Inc. 17
Anthera Pharmaceuticals� Inc. 18
Aprogen, Inc. 19
ChemoCentryx, Inc. 20
Clearside BioMedical, Inc. 21
Epirus Biopharmaceuticals, Inc. 22
F. Hoffmann-La Roche Ltd. 23
GlaxoSmithKline plc 24
Hemostemix Ltd 25
Hospira, Inc. 26
K-Stemcell Co., Ltd. 27
Panacea Biotec Limited 28
Pluristem Therapeutics Inc. 29
Sandoz Inc. 30
XOMA Corporation 31
Vasculitis - Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Target 33
Assessment by Mechanism of Action 35
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
ACP-01 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
belimumab - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
beperminogene perplasmid - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
blisibimod - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
CCX-168 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
gevokizumab - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
rituximab biosimilar - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
rituximab biosimilar - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
rituximab biosimilar - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
rituximab biosimilar - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
rituximab biosimilar - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
rituximab biosimilar - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
Stem Cell Therapy for Cardiovascular Diseases - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
tocilizumab - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
triamcinolone acetonide - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Vascostem - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Vasculitis - Recent Pipeline Updates 73
Vasculitis - Dormant Projects 99
Vasculitis - Product Development Milestones 100
Featured News & Press Releases 100
Dec 04, 2014: ChemoCentryx Granted EU Orphan Drug Designation for CCX168, an Orally Administered Complement C5a Receptor Inhibitor, for the Treatment of Microscopic Polyangiitis and Granulomatosis With Polyangiitis, Two Forms of ANCA-Associated Vasculitis 100
Jun 03, 2014: ChemoCentryx's CCX168, an Orally Administered Complement C5a Receptor Inhibitor, Granted Orphan-Drug Designation in ANCA-Associated Diseases by the FDA 100
Apr 03, 2013: GlaxoSmithKline Starts Phase III Study Of Benlysta In Patients With Vasculitis 101
Jan 10, 2013: Clearside Biomedical Announces Plans For Clinical Testing Of CLS1001 Suprachoroidal Injectable Suspension For Treatment Of Some Eye Diseases 101
Aug 17, 2012: Anges Announces Publication Of Long-Term Phase I/II Trial Data Of Collategene In Medical Journal 101
Aug 16, 2012: Pluristem Receives Approval From Indian Ministry Of Health For Use Of PLX Cells In Phase II Trial For Treatment Of Buerger's Disease 102
May 26, 2012: ChemoCentryx Presents Data on CCX168 At 49th European Renal Association-European Dialysis And Transplant Association Congress 102
Oct 17, 2011: ChemoCentryx Initiates Phase II Clinical Trial For CCX168 In Vasculitis 103
Mar 24, 2011: AnGes Publishes Results Of Collategene Study In International Angiology 104
Appendix 105
Methodology 105
Coverage 105
Secondary Research 105
Primary Research 105
Expert Panel Validation 105
Contact Us 106
Disclaimer 106

List of Tables
Number of Products under Development for Vasculitis, H2 2014 9
Number of Products under Development for Vasculitis - Comparative Analysis, H2 2014 10
Number of Products under Development by Companies, H2 2014 11
Comparative Analysis by Late Stage Development, H2 2014 13
Comparative Analysis by Clinical Stage Development, H2 2014 14
Comparative Analysis by Early Stage Development, H2 2014 15
Products under Development by Companies, H2 2014 16
Vasculitis - Pipeline by AnGes MG, Inc., H2 2014 17
Vasculitis - Pipeline by Anthera Pharmaceuticals� Inc., H2 2014 18
Vasculitis - Pipeline by Aprogen, Inc., H2 2014 19
Vasculitis - Pipeline by ChemoCentryx, Inc., H2 2014 20
Vasculitis - Pipeline by Clearside BioMedical, Inc., H2 2014 21
Vasculitis - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2014 22
Vasculitis - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 23
Vasculitis - Pipeline by GlaxoSmithKline plc, H2 2014 24
Vasculitis - Pipeline by Hemostemix Ltd, H2 2014 25
Vasculitis - Pipeline by Hospira, Inc., H2 2014 26
Vasculitis - Pipeline by K-Stemcell Co., Ltd., H2 2014 27
Vasculitis - Pipeline by Panacea Biotec Limited, H2 2014 28
Vasculitis - Pipeline by Pluristem Therapeutics Inc., H2 2014 29
Vasculitis - Pipeline by Sandoz Inc., H2 2014 30
Vasculitis - Pipeline by XOMA Corporation, H2 2014 31
Assessment by Monotherapy Products, H2 2014 32
Number of Products by Stage and Target, H2 2014 34
Number of Products by Stage and Mechanism of Action, H2 2014 36
Number of Products by Stage and Route of Administration, H2 2014 38
Number of Products by Stage and Molecule Type, H2 2014 40
Vasculitis Therapeutics - Recent Pipeline Updates, H2 2014 73
Vasculitis - Dormant Projects, H2 2014 99